Clinical Trials

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With = 1 cm Residual Invasive Cancer or Positive Lymph Nodes (ypN+) After Neoadjuvant Chemotherapy


Study ID
SWOG S1418-JTCC

NCT Number
NCT02954874 (Click on the NCT number for more information about the trial)

Research Study Number
2017-0041

Principle Investigator
Dr. Deena Graham

Phase
III

Sponsor
SWOG


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now